TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04935099

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild blueberry powder
Description: 22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild blueberry powder
Description: 22 g freeze-dried wild blueberry (Vaccinium angustifolium) powder, mixed with 250 ml water, and served in an opaque container.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: 22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo powder
Description: 22 g placebo powder matched for macronutrients and flavor, mixed with 250 ml water, and served in an opaque container.
Study: NCT04350775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RE-IADL
Description: RE-IADL program is to conduct trainings related to instrumental activities of daily living. For example,using communication appliance, moving in community, financial management, health care, housework, prepare meals and clear ,and shopping.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General community rehabilitation
Description: General community rehabilitation contains the activities in psychiatric rehabilitation center.
Study: NCT04648605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Post traumatic stress disorder questionnaire
Description: Parents of hospitalized children in pediatric resuscitation carry out a validated questionnaire that validates the post-traumatic stress level by a score.
Study: NCT04772040

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: Fish oil capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: Fish oil capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: Fish oil capsules.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation
Description: Fish oil capsules.
Study: NCT06095661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REAL System i-Series VR head-mounted display (HMD) from Penumbra, Inc.
Description: The VR intervention will use the REAL System i-Series VR head-mounted display (HMD) with built-in audio purchased from Penumbra, Inc. The i-Series is a gazed-controlled and fully immersive VR headset preloaded with immersive environments that promote positive distraction and relaxation through interactive experiences. These VR experiences include mindful meditation, travel, various nature scenes, and game experiences. REAL i-Series is classified as an unclassified product with product code PWC, a general wellness product FDA #3005168196.
Study: NCT05017207

Intervention type: PROCEDURE
Intervention: Pancreaticoduodenectomy
Description: Pancreaticoduodenectomy with one of 2 types of pancreaticojejunal anastomosis: Blumgart and conventional duct-to-mucosa
Study: NCT05432882

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bi-4SCAR CD19/22 T cells
Description: Infusion of bi-4SCAR CD19/22 T cells at 10\^6 cells/kg body weight via IV
Study: NCT06503575

Intervention type: OTHER
Intervention: Assesment
Description: All assessments will be made

Intervention type: OTHER
Intervention: Assesment
Description: All assessments will be made
Study: NCT05023408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin Injection
Description: Intralesional Bleomycin used for treatment of cutaneous warts.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryotherapy
Description: Cryotherapy used for comparison of efficacy.
Study: NCT06194136

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PBM light therapy
Description: The PBM machine consists of a dual light emitting diode (LED) cluster array with 105 light diodes within the 660 nanometer (nm) red light wavelength and the 850 nm near-infrared light wavelength. These wavelengths are both within the ranges noted in previous literature for neuropathic pain (1) and are within the World Association for Photobiomodulation (Laser) Therapy (WALT) guidelines for PBM therapy (2). Dosage will be determined according to the following equation: Laser output Power (Watts) x Time (seconds) divided by Beam Area (cm2)= J/cm2 (1). The PBM unit generates energy equal to 115 mW/cm2 with a surface area of 54.6 cm x 17 cm. Thus, for a target power output of 3.45 J, the participant will have a continuous irradiation duration of 30 seconds for each application (1). The participant will be asked to utilize the PBM device on breast tissue post-mastectomy for 30 seconds 3 times per week with at least 24 hours between each session. The duration of treatment will be 6 weeks.
Study: NCT05884931

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexpowder
Description: Hemostatic powder for endoscopy after colonoscopy polypectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Treatment
Description: Standard hemostatic procedure
Study: NCT05245331

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peristeen® Transanal irrigation system with the conic catheter
Description: The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Peristeen® Transanal irrigation system with the conic catheter
Description: The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard reusable enema
Description: The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard reusable enema
Description: The High-TAI (400-1000ml) will be self-performed using the Peristeen® Transanal irrigation system with the conic catheter every 48 hours during the first two week of treatment. Then patients could change frequency and volume of TAI depending on their needs and/or preference.~The Low-TAI will be self-performed using a standard 250ml water enema every 48 hours during the first two week of treatment. Then patients could change frequency of TAI depending on their needs and/or preference.
Study: NCT05412056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: as in arm/group description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: as in arm/group description
Study: NCT05975606

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation (rTMS)
Description: rTMS will be applied to primary motor cortex of the brain.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: functional electrical stimulation (FES) cycling
Description: FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation (FES) cycling
Description: FES will be applied to muscles associated in cycling: quadriceps, hamstrings, tibialis anterior, gastrocnemius, soleus.
Study: NCT03681314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 10-15 seconds.
Study: NCT05605002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: SSRIs
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRIs
Description: SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist. Once daily for 6 weeks.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: SIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body. SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day. A total of 10 sessions will be performed over a period of 6 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AIA
Description: This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7). Depending on acupoints' location, a φ0.20\*1.5mm or φ0.20\*1.2mm AIA will be selected. Press the AIA to insert it vertically into the acupoint and retain it in the skin. AIA will be retained for 72 hours with a day's rest after removal. During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours. A total of 10 sessions will be performed over a period of 6 weeks.
Study: NCT05291676

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone
Description: Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone
Description: Fluzone High-Dose 0.7 ml intramuscular injection, standard as recommended by manufacturer

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluad
Description: Fluad Quadrivalent, MF59 adjuvanted 0.5 ml intramuscular injection, standard as recommended by manufacturer
Study: NCT05574595

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music theraphy
Description: In each session, the desired type of music will be played approximately 6 minutes before the procedure (Shabandokht-Zarmi et al., 2017). After the end of the music, the cannulation process will be performed by the dialysis nurse. The level of pain experienced by the patient immediately after needle insertion into the fistula will be evaluated with VAS by a research-independent nurse working in the dialysis unit.
Study: NCT06439212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginger powder capsule
Description: Patient will receive one capsule of 500mg ginger powder capsule thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient will receive one capsule of placebo thrice daily for two days. First dose will be administered 1 hour before starting endodontic treatment.
Study: NCT06451445

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Irreversible Electroporation (NanoKnife)
Description: Irreversible Electroporation (IRE) using NanoKnife technology uses high voltage current pulses via probes placed around the prostate tumour via the perineum. The electricity damages the cell membranes rendering the cells dead. Hypothesized benefits of IRE over other focal therapy options include the ability to treat large or small lesions. Also, because the technology spares vessels, it can be used to treat prostate areas adjacent to sensitive structures (ie prostate apex near the sphincter and lateral peripheral zone near the neurovascular bundle). Finally, treatments take approximately 1-1.5 hours, thus the technology could be used to treat several patients per day.
Study: NCT06143332

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Aerobic exercise training on a cycle ergometer

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training
Description: Aerobic exercise training on a cycle ergometer
Study: NCT04782544

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Buttermilk Powder
Description: Treatment with 5.0 g of buttermilk powder daily for 10 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Anhydrous Milk Fat
Description: Treatment with 5.0 g of milk powder (90% anhydrous milk fat, 10% buttermilk powder) daily for 10 weeks.
Study: NCT05947487

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD70-targeting CAR-T cells
Description: Dose escalation:~Dose1 (1×10\^6 cells/kg) , Dose 2(3×10\^6 cells/kg) ,Dose 3 (1×10\^7cells/kg);~Dose expansion: RP2D~Drug: Albumin-bound paclitaxel~Administered intravenously at dose of 100-200mg/m2 on day -5;~Drug: Cyclophosphamide~Administered intravenously at dose of 15-30mg/kg on day -3 and day -2;~Drug: Fludarabine~Administered intravenously at dose of 30mg/m2 on day -3 and day -2;
Study: NCT06385249

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navina Mini
Description: Trans-anal irrigation (TAI) with a new CE-marked device, Navina Mini
Study: NCT05091463

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biostim-5/Neostim transcutaneous spinal stimulator
Description: Transcutaneous spinal stimulation (scTS): The 5-channel stimulator capable of generating pain-free biphasic rectangular waveform of 0.3 to 1.0 ms pulses with a frequency of 5-10 kHz will be used to stimulate at single or multi-site spinal levels. Transcutaneous stimulation will be delivered in combination with activity based locomotor training in 5-10 minute bouts of stimulation at sub-motor threshold during daily sessions (5x/week) lasting for 90 minutes for a total of 60 sessions of therapy. The sessions will consist of 55-60 minutes on the treadmill for facilitated standing/stepping followed by 30 minutes of activities off the treadmill in sitting, standing, or stepping.
Study: NCT05807360

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid eye drops
Description: Hyaluronic acid (HA)-based eyedrops
Study: NCT05798442

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: smartphone health application (Opulse)
Description: The Opulse app will be designed as a multifunction app that targets the modification of the behavioral and metabolic risk factors and provides comprehensive interventions for healthy diet, physical activity and smoking cessation among smokers.
Study: NCT05913661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib is scheduled to be administered at a dose of 13.5 mg quaque die according to a 2-week dosing and 1-week discontinuation regimen.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitors
Description: The dosing regimen is 200 mg IV Q3W
Study: NCT05418400

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X
Description: dental filling materials

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: sonic fill 3 & PALFIQUE bulk flow & Neo spectra & Clear fill AP-X
Description: dental filling materials
Study: NCT06389864

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS (repetitive transcranial magnetic stimulation)
Description: non invasive repetitive transcranial magnetic stimulation rTMS was administered at 10 Hz directed to the right dorsolateral prefrontal cortex. The pulse intensity was set at 80% of the observed motor threshold, 4 s on-train, 26 s off inter-train interval with 2000 pulses per session for 5 sessions per week, for 15 sessions total (i.e., 30,000 pulses total in treatment course) in the active TMS condition. For the sham rTMS, the coil was tilted over the right dorsolateral pre-frontal cortex without touching the scalp.
Study: NCT05953142

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dobutamine
Description: Intravenous infusion of dobutamine in incremental dosis according to perfusion markers for a period of 48 hours after randomization.
Study: NCT06496282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lemborexant
Description: The participants will receive lemborexant for improving sleep quality at lease 30 days in 6 weeks of study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The participants will receive placebo for improving sleep quality at lease 30 days in 6 weeks of study
Study: NCT05754385

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory monitoring of liver fat
Description: Participants will be given a novel portable, home-based device called the Gense-EIT liver scan the participants and will practice ambulatory liver fat monitoring for 6 months.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Subjects will have follow-up every 6 months by hepatologists for routine care
Study: NCT05021107

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FDM with isometrics
Description: FDM with isometrics will be done

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FDM without isometrics
Description: FDM without isometrics will be done
Study: NCT06119867

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Japanese pathological investigation
Description: Japanese pathological investigation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: European pathological investigation
Description: The European pathology evaluation method involves the analysis of fresh and intact specimens. Pathologists carefully inspect the entire specimen's appearance and assess the surgical resection plane and capture complete photographs for documentation purposes before further sectioning the specimen. During specimen processing, the CRM is initially marked with ink or other markers. After fixation, macroscopic data are recorded, and the entire length of the intestine is cut into cross-sections at intervals of 3-4 millimeters. These sections are then undergoing subsequent systematic pathological examination. However, the surgeon will be involved in the Japanese pathological investigation method. Intraoperative markings will be made 10 cm bilaterally from the primary tumor area. The resected colon will be incised at 1 cm intervals, after which the pericolic lymph nodes will be harvested. Each single retrieved lymph node will be packed up independently and will be examined by the pathologist.
Study: NCT06361732

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04776733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: prepackaged semisolid nutritional formulations
Description: The day before the colonoscopy: 3 bags of pre-packaged food were used for diet preparation.~On the day of the colonoscopy: a bag of pre-packaged food were used for breakfast.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: restricted diet
Description: The day before the colonoscopy: restricted diet prepared by patients were used for diet preparation.~On the day of the colonoscopy: restricted diet prepared by patients were used for breakfast.
Study: NCT05650814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ButterfLife
Description: On day 1, the investigator delivers the ButterfLife device at home and explains its use. The patient is recommended to take the measurement once a day, preferably in the morning and to repeat the measurement of parameters during the day if necessary. The doctor will check the data recorded by the patient every day and the trend of the parameters over time by a graphical representation on the electronic medical record (Vitaever®, Nethical S.r.l.). Daily telemonitoring will be conducted in addition to standard home care.

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Patients will receive standard home care: visits will be planned according to the patient's needs. In case of an unstable clinical condition, worsening of symptoms, and alteration of vital parameters, patient can contact by phone the physician or the nurse, who will decide how to intervene.
Study: NCT06475066

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: contrast-enhanced spectral mammography
Description: After enrollment, subjects should undergo contrast-enhanced spectral mammography again within within 28 days of MRI examination.~Iopromide/contrast agent is intravenously administered two minutes prior to the first (dual-energy) image acquisition.~* The dosage of iodine contrast agent is calculated as 1.5 mL/kg of iopromide 370 mgI/ml.~* Injecting with high pressure syringe (Stellant, Bayer AG) at an IDR of 3ml/s, followed by 10 ml normal saline.